
Biogen Inc.

BIIB (Biogen Inc.) trades at 3.2x EV/Revenue — attractively valued for a biotech & healthcare company with best-in-class gross margins (71%) and mature growth profile. The business is highly profitable at 32% EBIT margins. Forward PE of 12x.
80% of day traders lose money. The average holding period of a stock on the NYSE is now just 5.5 months — down from 8 years in 1960.
Gold Eagle provides data and AI-generated analysis for informational purposes only. Not investment advice. All data from public sources.
Biogen is a leading biotechnology company that develops and commercializes therapies for neurological and neurodegenerative diseases, with a primary focus on multiple sclerosis (MS), Alzheimer's disease, and spinal muscular atrophy. They generate revenue through prescription drug sales to patients via healthcare providers, with flagship products including Tecfidera for MS and the controversial Alzheimer's drug Aduhelm. The company combines internal R&D with strategic partnerships to bring complex neurological treatments to market.
Biogen faces near-term headwinds as core MS products face biosimilar pressure, but the company is banking on Alzheimer's franchise expansion and pipeline advancement to reignite growth. The Alzheimer's market opportunity exceeds $10 billion globally, while new MS therapies and expansion into adjacent neurological conditions provide additional upside. Revenue growth has been volatile, declining in recent years due to competitive pressures.
Biogen maintains strong gross margins above 85% typical of biotech companies, but operating margins have compressed due to heavy R&D spending and Aduhelm launch costs. The company generates substantial free cash flow from its established MS portfolio, though profitability outlook depends heavily on successful commercialization of newer products. Margin expansion potential exists if Alzheimer's franchise gains traction and pipeline assets reach market.
Biogen pioneered the MS treatment space and maintains market leadership despite increased competition from Roche, Novartis, and others. The company's deep neuroscience expertise and specialized commercialization capabilities create barriers to entry, though its competitive moat has narrowed as larger pharma companies enter key therapeutic areas. Patent protection remains crucial for maintaining pricing power and market position.
Limited recent financial data makes momentum assessment challenging, but Biogen has faced significant headwinds from Aduhelm's troubled launch and ongoing MS franchise pressure. The company has undergone management changes and strategic reviews to refocus priorities and cut costs. Market sentiment has been negative due to execution concerns and pipeline development delays.
Analyst sentiment on Biogen remains divided, with bulls pointing to undervalued Alzheimer's opportunity and pipeline potential while bears focus on core business decline and Aduhelm's commercial struggles. Consensus expectations reflect cautious optimism about long-term prospects tempered by near-term execution risks. The stock trades at significant discount to historical multiples reflecting uncertainty about growth trajectory.
Biogen is a high-risk, high-reward neuroscience leader at an inflection point—success in Alzheimer's and pipeline execution could drive substantial returns, but continued commercial stumbles could accelerate the decline of its core franchise.
Pre-generated investor questions answered by Claude Opus. Available in the Atlas AI tab.








| '25E | '26E | '27E | '28E | |
|---|---|---|---|---|
| Revenue | — | $9.4B | $9.4B | $9.5B |
| Growth | — | (1%) | +1% | |
| EBITDA | — | $3.0B | $2.9B | $3.0B |
| Growth | — | (1%) | +1% | |
| EPS (PF) | — | $15.76 | $16.18 | $17.34 |
| Growth | — |
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
Biogen Inc. (BIIB) Presents at Stifel 2026 Virtual CNS Forum Transcript
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
| +3% |
| +7% |
Biogen Inc. (BIIB) Presents at Leerink Global Healthcare Conference 2026 Transcript